{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46"}]}],"title":"Stable MR4.5 for 48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"}]}],"title":"Stable MR4.5 for 96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"title":"Stable MR4.5 for 144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"Stable MR4.5 for 192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"Stable MR4.5 for 240 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"Stable MR4.5 for 288 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Stable MR4.5 for 336 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Stable MR4.5 for 384 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Stable MR4.5 for 432 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Percentage of participants who were in stable MR4.5 (stable MR4.5=BCR-ABL ≤ 0.0032% IS) at multiple time points after achievement of that response in the nilotinib re-initiation phase for those timepoints.","groups":[{"description":"If a patient had a confirmed loss of MR4 (two consecutive BCR-ABL1 \\>0.01% IS) or loss of MMR (BCR-ABL1 \\>0.1% IS) in the TFR phase, the patient restarted nilotinib treatment.","id":"OG000","title":"NTRI Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Nilotinib treatment re-initiation (NTRI) Safety set included participants who achieved MR4.5 at least once in nilotinib re-initiation phase","reportingStatus":"POSTED","timeFrame":"at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks","title":"Proportion of Participants With Stable MR4.5 in Nilotinib Re-initiation Phase","type":"SECONDARY","unitOfMeasure":"Participants"}